8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K



              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 29, 2005


                         Commission File Number 1-09623


                                IVAX CORPORATION



              Florida                                    16-1003559
  -------------------------------                    -------------------
  (State or other jurisdiction of                     (I.R.S. Employer
   incorporation or organization)                    Identification No.)


                  4400 Biscayne Boulevard, Miami, Florida      33137
               -------------------------------------------------------
               (Address of principal executive offices)     (Zip Code)


                                 (305) 575-6000
                                 --------------
              (Registrant's telephone number, including area code)

Check the appropriate box if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (See General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 13e-4(c))





Item 5.02  Departure of Directors or principal Officers; Election of Directors;
Appointment of Principal Officers.

On April 29, 2005, Avram Hershko, M.D., Ph.D. and Zachariah Zachariah were
nominated and appointed to the board of directors of IVAX Corporation. On April
29, 2005, Drs. Krasno and Zachariah's appointment was announced by IVAX in a
press release which is attached hereto as Exhibit 99.1 and incorporated by
reference herein.

On April 29, 2005, the board of directors approved the slate of directors for
election at the 2005 annual meeting of shareholders as follows:
Betty G. Amos
Mark Andrews
Jack Fishman, Ph.D.
Neil Flanzraich
Phillip Frost, M.D.
Avram Hershko, M.D., Ph.D.
Jane Hsiao, Ph.D.
Richard M. Krasno, Ph.D.
David A. Lieberman
Richard C. Pfenniger, Jr.
Bertram Pitt, M.D.
Zachariah P. Zachariah, M.D.

As previously announced, Ernst Biekert, Ph.D. and Paul Cejas have determined not
to stand for reelection to the board of directors. On April 29, 2005, Bruce
Greer decided that he will not stand for reelection to the board of directors.
Dr. Biekert and Messrs. Cejas and Greer will continue to serve on the board of
directors until the 2005 Annual Meeting of Stockholders.








                                   Signatures
                                   ----------

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                               IVAX Corporation



     Date: May 02, 2005                        By: /s/ Thomas E. Beier
                                                   -----------------------------
                                                   Thomas E. Beier
                                                   Senior Vice President-Finance
                                                   Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1

IVAX Elects Avram Hershko, M.D., Ph.D. and Zachariah P. Zachariah, M.D.
                         to Board of Directors

    MIAMI--(BUSINESS WIRE)--April 29, 2005--IVAX Corporation
(AMEX:IVX) (LSE:IVX.L) (WSE:IVX) announced the nomination and
appointment of Avram Hershko, M.D., Ph.D. and Zachariah P. Zachariah,
M.D. to its Board of Directors.
    Dr. Hershko has served as a Distinguished Professor since 1998 and
as Professor, Unit of Biochemistry, Faculty of Medicine since 1980, at
the Technion-Israel Institute of Technology in Haifa Israel. Dr.
Hershko received his M.D. in 1965 and his Ph.D. in 1969 from the
Hebrew University - Hadassah Medical School in Jerusalem Israel. He
was awarded the Nobel Prize in Chemistry in 2004.
    Dr. Zachariah is CEO and President of the Fort Lauderdale Heart
Institute. He has also served since 1995 as a Director of Cardiology
at Holy Cross Hospital in Fort Lauderdale. He has served as a member
of the Florida State Board of Governors since 2003 and as Chairman of
the Florida Council on Economics Education since 2003.
    Phillip Frost, M.D., chairman and chief executive officer of IVAX,
said, "Dr. Hershko and Dr. Zachariah both bring great knowledge and
experience to the IVAX Board. We are fortunate to have the benefit of
their participation in IVAX' future."
    IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.
    Copies of this and other news releases may be obtained free of
charge from IVAX' Web site at http://www.ivax.com.

    CONTACT: IVAX Corporation, Miami
             David Malina, 305-575-6043